Tilray (NASDAQ:TLRY) released its earnings results on Sunday. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.12, Fidelity Earnings reports. Tilray had a negative return on equity of 4.25% and a negative net margin of 83.14%. The firm had revenue of $155.10 million for the quarter, compared to the consensus estimate of $171.57 million. The firm’s revenue was up 19.8% on a year-over-year basis.
TLRY traded up $0.05 during mid-day trading on Tuesday, hitting $7.34. 995,746 shares of the stock were exchanged, compared to its average volume of 39,623,484. The firm’s fifty day moving average is $9.36 and its two-hundred day moving average is $11.87. Tilray has a 1-year low of $6.29 and a 1-year high of $67.00. The company has a current ratio of 1.60, a quick ratio of 1.13 and a debt-to-equity ratio of 0.18. The company has a market cap of $3.38 billion, a PE ratio of -3.60 and a beta of 2.39.
A hedge fund recently raised its stake in Tilray stock. UBS Group AG lifted its holdings in shares of Tilray Inc (NASDAQ:TLRY) by 44.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 132,170 shares of the company’s stock after acquiring an additional 40,802 shares during the period. UBS Group AG’s holdings in Tilray were worth $1,492,000 at the end of the most recent reporting period. 11.04% of the stock is owned by hedge funds and other institutional investors.
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Recommended Story: How Important is Technical Analysis of Stocks
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.